Adaptive and Oxford Immunotec think T cell tests could uncover COVID-19 patients and biology missed by other assays.
As Regeneron’s long tie-up with Sanofi winds down, the big biotech faces choices about how to commercialize its next slate of therapeutics.
In a Juneteenth commentary, BioCentury’s co-founders provide a starter list of actions for biopharma to address racial disparities in healthcare.
Readouts from 25 controlled trials for COVID-19 start to flesh out a treatment paradigm.
A survey of U.K. biotechs finds high confidence private companies can raise the money they need, and a willingness to turn to VCs globally.
FDA and biopharma companies are using real-world data from online initiative BEAT19 to inform the design of trials for COVID-19 therapies.
Guest commentary: China is open for clinical trials and can offer Western companies long-term strategic opportunities in addition to crisis management.
The World Economic Forum is leading the establishment of a consortium that will bring the capabilities of vaccine manufacturers outside the U.S. and Europe into the fight against COVID-19.
The White House presents a high-level road map to its plans to produce 300 million COVID-19 vaccine doses by January.
Orca Bio is developing allogeneic cell therapies that use controlled formulations designed to reduce toxicity compared with traditional bone marrow transplants.
Following an August $31M series A and CSL deal, Lassen has emerged from Frazier with a mAb for cancer and fibrosis and Fujifilm manufacturing deal.
A reevaluation of old data, plus new clinical evidence, prompted FDA to rescind authorization of the two antimalarials to treat COVID-19.
The threat of vaccine nationalism and the forces working against it.
A global funding initiative is trying to prevent a chaotic scramble for COVID-19 vaccines and ensure equitable access.
The European Commission launches an EU-wide procurement strategy to ensure equitable access to COVID-19 vaccines in Europe.
While in lockdown, two T cell companies closed a deal to develop personalized, exhaustion-resistant therapies for solid tumors.
GSK and Ideaya’s deal is the second in a month to bring a pharma deeper into synthetic lethality.
Round from European syndicate is designed to deliver initial clinical results from basket trial
Demand remained high as more biotechs tested the market, while others piled into the queue.
BioCentury ISSN 1097-7201
